• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Valeant Pharmaceuticals launches patient access and pricing committee

Valeant Pharmaceuticals launches patient access and pricing committee

May 9, 2016
CenterWatch Staff

Valeant Pharmaceuticals International has formed a new patient access and pricing committee that will be responsible for the pricing of the company's drugs. The committee will be chaired initially by Joseph Papa, chairman and chief executive officer of Valeant, and will include a multi-disciplinary team of Valeant employees, including doctors, scientists and other executives.

The company's board of directors will oversee the patient access and pricing committee. The company has recently added new members to its board and announced the nomination of additional board members who together bring significant experience in physician and patient access, legal and regulatory affairs and the pharmaceutical industry. Among other issues, the committee will review the pricing of Nitropress, Isuprel, Cuprimine and Syprine.

"Valeant has made mistakes in how it priced its drugs in the past, and we are committed to ensuring those mistakes are not repeated," said Joseph Papa, chairman and chief executive officer. "This new committee will take a disciplined approach to reviewing the company's pricing of drugs, and will consider the impact on patients, doctors and our healthcare industry partners. Valeant's number one priority is ensuring patients can access the medicines they need."

Since last week's hearing before the Senate Aging Committee, Valeant has reached out to hospitals to follow up on concerns raised that they had not received expected discounts on Nitropress and Isuprel. The company will continue to work with hospitals to ensure they have access to the two drugs.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing